Canadian Blood and Marrow Transplant Group
Cure Stems From Here
Events
Past Webinars
Digital copies of the webinar will also be available for purchase:
Members: $70 plus tax
Non-members: $90 plus tax
Click here to order a webinar recording online
Click here to download a PDF Digital Recording order form
November 23, 2011
12 pm ET
Quality of Life of Children and their Parents
and the Impact on Family of Pediatric Hematopoietic Stem Cell Transplantation
Stacey Pollock-BarZiv, Phd
The
Hospital for Sick Children/University of Toronto, SickKids Transplant Centre
John Doyle, MD
Tal Schechter, MD
The
Hospital for Sick Children/University of Toronto, Pediatric Hematology/Oncology
Learning objectives and synopsis of the presentation:
This presentation summarizes the key findings of a prospective study of the multidimensional aspects of Quality of Life (QOL) over the first year after pediatric hematopoietic stem cell transplantation (HSCT).
Specific attention will be focused on:
- Elucidating key physical, psychological, social and cognitive aspects of function that impact QOL from both the child and parents perspective, and evaluate these changes over time in the first year after transplant. These results will be compared to normative data to provide perspective on how these children and families are impacted.
- Compare results of children’s perceived functional status compared to their parents
- Ascertain the ‘impact on family’ of HSCT over the first year
- Identify areas that warrant further attention, study and potential intervention to improve outcomes after HSCT
Click here to order the webinar recording online
Digital Recording order form (pdf)
November 2, 2011
12 pm ET
General Introduction to Cryobiology
Locksley McGann
Professor, Department of Laboratory Medicine and Pathology,
University of Alberta,
Laboratory Director, Edmonton Stem Cell Transplant
Program, Canadian Blood Services
This webinar will introduce basic principles of cryobiology and how the principles are applied to cryopreservation of viability and function in cells.
Webinar Objectives:
to understand
- changes that occur in a physiological solution at low temperatures
- responses of living cells exposed to those changes
- basic mechanisms of cryoinjury and cryoprotection
to illustrate
- applications of this understanding in:
- managing exceptions related to samples cryopreserved for transplantation
- shaping the future of cryopreservation related to cellular therapies
Click here to order the webinar recording online
Digital Recording order form (pdf)
June 22, 2011
12:00 pm ET
"NK Cell Line Therapy for Leukemia" (2009 Keating Group Small Budget Research Grant)
Brent Williams, BSc (Hon), BSc(Med), MD, FRCP(C), FAAP
Fellow, Division of Hematology/Oncology
Associate Staff, Division of Emergency Medicine
The Hospital for Sick Children
Resident, Royal College Clinician Investigator Program
PhD candidate, Institute of Medical Sciences, University of Toronto
Cell Therapy Program, Princess Margaret Hospital
- Understand the leukemia stem cell hypothesis and its clinical relevance.
- Understand the clinical evidence for NK cell therapy for acute myleoid leukemia (AML).
- Understand the principles behind cell line therapy for cancer.
- Review pre-clinical data for NK-92 and KHYG-1 against AML.
- Discuss application of Good Manufacturing Practice (GMP) facilities in cell therapy.
Click here to order the webinar recording online
May 25, 2011
12pm ET
"DREAM" - A Change Management Tool for
Interdisciplinary Process Implementation of ISBT 128 Labeling for
Cellular Therapy Programs
Patty Bakkestad-Legare, CHT, CHS, ART
Quality Assurance Manager, Manitoba Blood and Marrow Transplant Program
Marie Tulloch, MLT
Senior Technologist, Cellular Therapy Laboratory, CancerCare Manitoba
David Szwajcer, MD, MSc
Associate Medical Director, Cellular Therapy Laboratory, CancerCare Manitoba
Webinar Learning Objectives:
1. Understand how a LEAN Change Management Framework (DREAM) may be used to successfully implement ISBT 128 labeling for Cellular Therapy Programs.
2. Understand how ISBT 128 data structures work and how to perform and ISBT 128 label validation.
3. Understand how ISBT 128 enhances safety for patients by providing a global standard for cellular therapy identification with standardized labeling information.
Click here to order the webinar recording online
April 20, 2011
12pm ET
Pharmaceutical Management of Fungal Infections Post Transplant
Cindy Ippoliti, PharmD
Clinical Manager, BMT/Oncology, New York Presbyterian Hospital
During this webinar participants will:
Determine which patients are at greatest risk for the development of invasive fungal infections post stem cell transplant.
Discuss the prophylactic strategies in both low and high risk patients.
Compare the data from the clinical trials.
Design an appropriate patient specific regimen based on efficacy, toxicity and cost.
Click here to order the webinar recording online
March 23, 2011
12pm ET
Working with Hematological Cancer Patients and Families - Is Compassion Fatigue Inevitable?
Brenda Sabo, RN, BA, MA, PhD
Assistant Professor, School of Nursing, Dalhousie University
Objectives:
- Introduce the concept of compassion fatigue.
- Provide an overview of the relationship between compassion fatigue and other forms of occupational stress.
- Introduce de novo finding: compassionate presence.
- Provide key messages for practice, education and research.
Click here to order the webinar recording online
February 23, 2011
12pm ET
Chronic GVHD Biomarkers
Dr. Kirk Schultz, MD
Associate Professor of Pediatrics, B.C. Children's Hospital
Click here to order the webinar recording online
October 27, 2010
12pm ET
Expanding Options and Current Challenges in Autologous PBPC Harvests
Ronan Foley, MD, FRCPC
Director of the Stem Cell Laboratory, Hamilton Health Sciences
Objectives:
- Upfront identification of patients at risk
- Treatment options and Algorithms
- New Agents and the Future
Dr. Ronan Foley is a clinical haematologist and Director of the Stem Cell Laboratory, Hamilton Health Sciences. Over the past 4 years Dr. Foley has acted as Chair of the Clinical Trials Network of the Canadian Bone Marrow Transplant Group (CBMTG). An Associate Professor of Pathology and Molecular Medicine at McMaster University, Dr. Foley completed his medical and subspecialty training in Hamilton and Toronto. He completed a Terry Fox Fellowship in the Centre of Gene Therapeutics, McMaster University. During this time, he became interested in the evaluation of cellular gene transfer in the context of cancer immunotherapy, which led to his current research focus: the development of therapeutic cancer vaccines.In addition to fundamental research the clinical laboratory has been active in novel clinical stem cell manipulations for haploidentical transplants and photodynamic therapy for GVHD and tumor cell purging (NHL).
First CBMTG Webinar:
"Challenges Faced with Cord Blood Transplants"
Donna Wall, MD, Director Blood and Marrow Transplant Program
Marie Tulloch, MLT (CSMLS) Senior LaboratoryTechnologist, Cellular Therapy Lab
CancerCare Manitoba
Wednesday, February 25, 2009
CD copies of the webinar available for purchase:
Members: $75 plus tax
Non-members: $90 plus tax
Click here to download a PDF CD order form
March Webinar:
“Sexuality in Patients Undergoing Hematopoietic Stem Cell Transplantation”
Reanne Booker, RN BScN, MN, Nurse Practitioner
Alberta Bone Marrow Transplant Program
Wednesday, March 25, 2009
12 PM EDT
Objectives:
* review the impact of stem
cell transplantation on sexuality
* discuss
assessment/management of sexual health concerns
* discuss resources
available for healthcare providers
April Webinar:
"Canadian Blood Services OneMatch Stem Cell and Marrow Network Update"
Sue Smith, Executive Director, OneMatch Stem Cell
and Marrow Network
April 22, 2009
12:00pm EDT
Objectives:
*increase overall awareness of the Onematch
Stem Cell and Marrow Network
*share
and discuss the latest statistics and data on unrelated hematopoietic stem cell
activities in Canada and Internationally
*provide and update on the status of the business case for
establishment of a national public umbilical cord blood bank
May Webinar:
"HLA Typing: Cases We Don't See Everyday"
Cindy Ellison, PhD, D(ABHI)
HLA Laboratory
CancerCare Manitoba
Geoff Cuvelier, MD, FRCPC
Pediatric Blood and Marrow Transplant Program
CancerCare Manitoba
May 27, 2009
12:00pm EDT
Objectives:
* Review HLA basics: structure, funcion, nomenclature, and typing methods.
*Using instructive cases, present approaches to family and extended kindred typing, recombination and mismatch evaluation.
June Webinar:
"Stem Cell Transplantation: Past, Present and Future"
Dr. Thomas Nevill
Clinical Director
Leukemia/BMT Program of British Columbia
June 24, 2009
12:00pm EDT
Supported by:
Objectives are to provide the participant with an understanding of:
1.The scientific basis of SCT.
2.The actual SCT process, from cell collection to infusion of the product.
3.The complications and expected outcomes for SCT recipients.
4.The new developments in the field of SCT.
September Webinar:
“Do NK Cells Contribute to Graft-Versus-Leukemia? Defining a Role for KIR Mismatching in AML Transplants."
Geoff Cuvelier, MD, FRCPC
Pediatric Blood and Marrow Transplant Program
CancerCare Manitoba
Wednesday, September 23, 2009
12 PM EDT
1. Review basic biology of NK cells
2. Review potential role for NK cells in graft-versus-leukemia effect
3. Review results and controversies in clinical trials looking at NK cell KIR mismatching in allogeneic HSCT.
October 2009 Webinar:
Young Adults with Cancer
Geoff Eaton
Founder and Executive Director
Young Adult Cancer Canada
Geoff Eaton
is a very proud Newfoundlander, who graduated from Memorial University
of Newfoundland, where he studied Business Administration. During his
final year of studies he created Exeter Imaging, a marketing services
company. Today he lives in St. John’s, NL, with his wife Karen and
daughters Adia and Mira, where he is the founder and Executive Director
of Young Adult Cancer Canada.
Originally diagnosed with
Leukemia in 1998 Geoff received several rounds of chemotherapy, full
body radiation, a bone marrow transplant from his Dad and later spent a
month in Intensive Care on life support. After rebuilding physically
and emotionally from his ICU experience Geoff turned his cancer
challenge into opportunity with the establishment of Young Adult Cancer
Canada (YACC).
As YACC celebrated its first anniversary of
operation Geoff's leukemia relapsed forcing an adjustment in personal
and professional plans. After additional chemotherapy and a stem cell
transplant, again from his Dad, Geoff resumed limited work activities.
Since
those early years YACC’s vision has evolved considerably, as has the
program offering for young adults dealing with cancer.
Today
YACC is the only Canadian cancer organization nationally focused on
inspiring, informing and supporting young adults dealing with cancer.
YACC hosts a web-based peer support community for young adult
survivors, annual retreats, a survivor conference and delivers Touch
Yourself, Trust Yourself, an early detection education program for
young adults.
Geoff is a member of the Canadian Association of
Professional Speakers and has shared his message of hope with over
65,000 people from across Canada. His story has been featured in
numerous national television, radio and newspaper outlets.
Professional
goals focus on filling the education and support gap for young adults
dealing with cancer through the growth of Young Adult Cancer Canada,
inspiring the masses to take control of their health and their life in
his professional speaking and working to improve the Canadian
healthcare system as a patient advocate.
Committed to
volunteering, Geoff is a member of the National Survivorship Working
Group and the Adolescent Young Adult Task Force, both initiatives of
the Canadian Partnership Against Cancer.
Geoff is personally
devoted to staying healthy, growing old with his wife and daughters and
the constant pursuit of the sometimes elusive state of balance.
You will not meet another person who embodies their motto as much as Geoff Eaton… Always… Live life, love life.
November Webinar:
"The Source of Cells for Allografting"
Stephen Couban, MD
Director, Bone Marrow Transplant Program
Queen Elizabeth II Health Sciences Centre
Wednesday, November 18, 2009
12:00 pm EST
Learning Objectives:
1. To understand the different sources of cells for allografting
2. To understand the potential complications of marrow harvesting and peripheral blood harvesting for the donor
3. To understand the potential advantages and disadvantages of marrow and peripheral blood for the recipient
4. To consider future directions in this field.
Stephen Couban received a
Bachelor of Science degree from McGill University in 1982 and his M.D.
from Dalhousie University in 1986.He completed a residency in Internal
Medicine at Dalhousie University in Halifax and went on to complete a
fellowship in Hematology at McMaster University in Hamilton.He also
undertook two years of specialty training in bone marrow
transplantation at the Princess Margaret Hospital in Toronto as a
National Cancer Institute of Canada Terry Fox Research Fellow.
In 1997, Stephen Couban joined the Department of Medicine at Dalhousie
University and the Capital District Health Authority in Halifax, Nova
Scotia. He is Service Chief in the Division of Hematology and Director
of the Blood and Marrow Transplant Program. He is also Service Chief of
the Department of Medicine Medical Teaching Unit.His research interests
have focused on allografting and in particular on exploration of
different types of grafts including G-CSF stimulated allogeneic
peripheral blood allografts and G-CSF stimulated bone marrow
allografts. Stephen Couban is Past-President of the Canadian Blood and
Marrow Transplant Group, Secretary of the Canadian Hematology Society
and Co-Chair of the Hematology Site Group of the National Cancer
Institute of Canada Clinical Trials Groups.
December 2009 Webinar:
“Acute Graft-versus-Host Disease Treatment Options: Facts and Controversies"
This program is supported through an unrestricted educational grant from Schering-Plough Canada Inc., now part of Merck.
Silvy Lachance, MD FRCPC CSPQ
Director Stem Cell Transplant Program
Maisonneuve-Rosemont Hospital
Wednesday, December 16, 2009
12:00 pm EST
Despite recent advance in the understanding of its pathophysiology, acute Graft versus Host Disease remains a major complication of allogeneic Stem Cell Transplantation. While initial treatment is relatively standardized, the approach to steroid refractory aGVHD continues to be a real challenge. No clear guidelines have emerged from the literature and comparative study between treatment alternatives is sadly lacking. The goal of the lecture is to review the efficiency of the different therapeutic options focusing on treatment selection according to the site or organ involved. An algorithm of treatment will be proposed.
Dr. Silvy Lachance received her M.D. degree in 1987 from the University of Sherbrooke where she completed an internship and residency training in Internal Medicine. She then moved to Montreal in 1990 and underwent a Fellowship in Hematology and Oncology at Montreal University. She left Canada in 1992, after receiving the Samuel H. McLaughlin Foundation Grant and a grant from the University of Sherbrooke to pursue a Fellowship in Stem Cell Transplantation in Paris at Henri-Mondor University. In Paris she worked in the transplant unit of Professor Jean-Paul Vernant and in the immunology laboratory of Professor Jean-Pierre Farcet in the exciting and evolving field of allogeneic stem cell transplantation. Her research project focused on Graft-versus-Host and Graft-versus-Leukemia reaction, developing functional assays looking at Cytotoxic and Helper T-cell precursors as predictive factors of GVH and GVL reaction. In 1994, she<